Skip to content

Unregulated Commerce of Erectile Dysfunction Drug Approved in Japan

Approval Granted for Over-the-Counter Sales by a Health Ministry Expert Panel in Tokyo, as of September 18th

Over-the-counter sales of an erectile dysfunction drug are now approved in Japan
Over-the-counter sales of an erectile dysfunction drug are now approved in Japan

Unregulated Commerce of Erectile Dysfunction Drug Approved in Japan

In a significant development, Tokyo-based drugmaker SSP Co. has applied for permission from the Japanese health ministry to sell Cialis, a drug used to treat erectile dysfunction, over-the-counter. If approved, Cialis will be the first erectile dysfunction treatment available for over-the-counter purchase in Japan.

SSP Co. has acquired a license for Cialis from Nippon Shinyaku Co., a drugmaker based in Kyoto, Japan. The over-the-counter sales of Cialis could potentially broaden access to erectile dysfunction treatment in Japan, offering increased opportunities for those seeking relief.

Under the current system, diagnoses and prescriptions by doctors are required to obtain erectile dysfunction drugs. However, the potential over-the-counter sales of Cialis could change this, making the treatment more accessible to a wider population.

The approval of Cialis for over-the-counter sales is pending public comments and the endorsement of the health minister in Japan, currently Takamaro Fukuoka. Guidance from pharmacists will be required for purchases of Cialis at drugstores in Japan, even after it becomes available over-the-counter.

Erectile dysfunction is identified as a factor contributing to declining birthrates in Japan. The over-the-counter sales of Cialis could potentially increase opportunities for erectile dysfunction treatment in Japan, which may have a positive impact on the country's demographic trends.

The Japanese health ministry has already approved over-the-counter sales of a drug to treat erectile dysfunction, setting a precedent for this potential change. The OTC sales of Cialis are pending the endorsement of the health minister after public comments are gathered.

This development comes as a response to the growing need for accessible healthcare solutions in Japan. It's a step towards making essential treatments more readily available, and a significant move in the country's healthcare landscape.

Read also:

Latest